What are you looking for?

Early Phase Clinical Trials in Patients with Hepatic or Renal Impairment

June 20, 2016
Download Now
FDA and EMA guidances are intended to help companies evaluate the need for conducting pharmacokinetic studies in renal and hepatic impaired patients and to provide guidance on how to best assess the influence of renal impairment or hepatic impairment on the pharmacokinetics of an investigational drug. However, while many procedural recommendations exist, some key questions still need to be investigated case-by-case at the early stage of the project development.
 
This white paper will address key questions that arise in this type of clinical trial, from design to data analysis.
Early Phase Clinical

Please complete the form to download your copy.

    News & Insights

    • SGS Headquarters

    1 Place des Alpes,

    P.O. Box 2152 1211,

    Geneva Switzerland